Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis

Journal of Infectious Diseases

Volumn 204, Issue 7, 2011, Pages 1026-1030

  Rulli, Nestor E ^a,b,c   Rolph, Michael S ^a,b   Srikiatkhachorn, Anon ^d   Anantapreecha, Surapee ^e   Guglielmotti, Angelo ^f   Mahalingam, Suresh ^a,b  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF CANBERRA   (Australia)

^c UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

^f Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BINDARIT; GAMMA INTERFERON; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFECTIOUS ARTHRITIS; INFLAMMATORY INFILTRATE; MOUSE; MYOSITIS; NONHUMAN; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ALPHAVIRUS INFECTIONS; ANIMALS; ARTHRITIS, INFECTIOUS; CHEMOKINE CCL2; CHIKUNGUNYA VIRUS; HUMANS; INDAZOLES; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MYOSITIS; PROPIONIC ACIDS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 80052410351     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir470     Document Type: Article

References (15)

1. Suhrbier A., Mahalingam S. The immunobiology of viral arthritides. Pharmacol Ther 2009; 124:301-308
2. Staples J.E., Breiman R.F., Powers A.M. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis 2009; 49:942-948
3. Borgherini G., Poubeau P., Staikowsky F., et al. Outbreak of chikungunya on Reunion island: Early clinical and laboratory features in 157 adult patients. Clin Infect Dis 2007; 44:1401-1407 (Pubitemid 46801580)
4. Borgherini G., Poubeau P., Jossaume A., et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on Reunion island. Clin Infect Dis 2008; 47:469-475
5. Tandale B.V., Sathe P.S., Arankalle V.A., et al. Systemic involvements and fatalities during Chikungunya epidemic in India, 2006. J Clin Virol 2009; 46:145-149
6. Labadie K., Larcher T., Joubert C., et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 2010; 120:894-906.
7. Hoarau J., Bandjee M., Trotot P., et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 2010; 184:5914-5927
8. Gardner J., Anraku I., Le T., et al. Chikungunya virus arthritis in adult wild-type mice. J Virol 2010; 84:8021-8032
9. Morrison T., Whitmore A., Shabman R., Lidbury B.A., Mahalingam S., Heise M.T. Characterization of Ross River virus tropism and virusinduced inflammation in a mouse model of viral arthritis and myositis. J Virol 2006; 80:737-749 (Pubitemid 43062886)
10. Lidbury B., Rulli N., Suhrbier A., et al. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis following infection with an arthrogenic alphavirus. J Infect Dis 2008; 197:1585-1593 (Pubitemid 351706489)
11. Mirolo M., Fabbri M., Sironi M., et al. Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw 2008; 19:119-122
12. Rulli N., Guglielmotti G., Mangano G., et al. Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis Rheum 2009; 60:2513-2523
13. Wells T., Power C., Shaw J., Proudfoot A.E. Chemokine blockerstherapeutics in the making? Trends Pharmacol Sci 2006; 27:41-47
14. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737-744
15. Zaid A., Rulli N.E., Rolph M.S., Suhrbier A., Mahalingam S. Disease exacerbation by etanercept in a mouse model of alphaviral arthritis and myositis. Arthritis Rheum 2011; 63:488-491